← All trials
NCT03228667
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2018
- Primary completion
- May 31, 2021
- Completion date
- Aug 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 105
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Altor BioscienceLead sponsor
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Stomach Neoplasms
- Colorectal Neoplasms
- Carcinoma, Merkel Cell
- Microsatellite Instability
- DNA Mismatch Repair
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.